Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of intravenous efgartigimod in acetylcholine receptor antibody-seronegative generalized myasthenia gravis
2024-511796-15-00Phase 3Authorised
- Sponsor
- argenx
- Start
- Oct 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial in myasthenia gravis (MG) comparing Vyvgart IV with Placebo IV (2 arms). Primary endpoint: MG-ADL total score change from baseline to day 29 in part A. Planned start Oct 2024; status: authorised.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2024-511796-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511796-15-00.